Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-02-09

FDA Approved: XYZAL — Supplemental Application (Chattem, Inc.)

View source ↗

Summary

FDA approved a supplemental application for XYZAL (levocetirizine dihydrochloride) from Chattem, Inc., approving changes to the product's labeling. This action …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • XYZAL (LEVOCETIRIZINE DIHYDROCHLORIDE)

Snippet

SUPPL AP for XYZAL (LEVOCETIRIZINE DIHYDROCHLORIDE)